| Id |
Subject |
Object |
Predicate |
Lexical cue |
| p1_all0 |
0-69 |
Population |
denotes |
Infection control O14 Surgical site infection surveillance in France: |
| p2_i0 |
264-289 |
Physical |
denotes |
hypochlorite disinfection |
| p1_all1 |
371-585 |
Population |
denotes |
Portuguese swine after growth promoter ban O27 European Antimicrobial Susceptibility Surveillance in Animals (EASSA): Results (2002/2003) for enteric bacteria from healthy cattle, pigs and chickens from 8 countries |
| p1_all2 |
1198-1201 |
Outcome |
denotes |
SSI |
| p1_all3 |
1324-1442 |
Outcome |
denotes |
age, ASA score, Altemeier wound class, type and duration of procedure, emergency/elective, and when videoscopy surgery |
| p1_all4 |
1613-1639 |
Outcome |
denotes |
overall SSI incidence rate |
| p2_o9 |
1613-1639 |
Physical |
denotes |
overall SSI incidence rate |
| p1_all5 |
1651-1686 |
Outcome |
denotes |
Organ space and deep incisional SSI |
| p2_o10 |
1651-1686 |
Physical |
denotes |
Organ space and deep incisional SSI |
| p1_all6 |
1774-1792 |
Outcome |
denotes |
SSI incidence rate |
| p2_i1 |
1831-1837 |
Pharmacological |
denotes |
NNIS-0 |
| p1_all7 |
1897-1910 |
Outcome |
denotes |
SSI incidence |
| p2_o12 |
1897-1910 |
Physical |
denotes |
SSI incidence |
| p1_all8 |
2025-2047 |
Outcome |
denotes |
SSI risk for C-section |
| p1_all9 |
2133-2153 |
Outcome |
denotes |
NNIS-0 SSI incidence |
| p1_all10 |
2595-2648 |
Outcome |
denotes |
Healthcare associated infection (HAI) incidence rates |
| p2_o18 |
2595-2648 |
Physical |
denotes |
Healthcare associated infection (HAI) incidence rates |
| p1_all11 |
2861-2896 |
Intervention |
denotes |
HAI continuous surveillance network |
| p1_all12 |
2897-2948 |
Population |
denotes |
on maternity units located in south eastern France. |
| p1_all13 |
2970-2993 |
Outcome |
denotes |
risk-adjusted HAI rates |
| p2_o21 |
2970-2993 |
Physical |
denotes |
risk-adjusted HAI rates |
| p1_all14 |
3066-3215 |
Population |
denotes |
Methods: 161,077 vaginal deliveries and 37,074 cesarean deliveries were included in the surveillance between January 1st 1997 and December 31st 2003. |
| p2_o23 |
3247-3264 |
Physical |
denotes |
HAI: endometritis |
| p1_all15 |
3247-3362 |
Outcome |
denotes |
HAI: endometritis and Urinary tract infection (UTI) after vaginal deliveries, surgical site infection (SSI) and UTI |
| p2_o23 |
3269-3298 |
Physical |
denotes |
Urinary tract infection (UTI) |
| p2_o23 |
3325-3354 |
Physical |
denotes |
surgical site infection (SSI) |
| p2_o23 |
3359-3362 |
Physical |
denotes |
UTI |
| p1_all16 |
3533-3556 |
Outcome |
denotes |
risk-adjusted HAI rates |
| p2_o26 |
3533-3556 |
Physical |
denotes |
risk-adjusted HAI rates |
| p2_o27 |
3686-3714 |
Physical |
denotes |
rate of endometritis and UTI |
| p1_all17 |
3686-3739 |
Outcome |
denotes |
rate of endometritis and UTI after vaginal deliveries |
| p1_all18 |
3838-3861 |
Outcome |
denotes |
endometritis odd ratios |
| p2_o28 |
3838-3861 |
Physical |
denotes |
endometritis odd ratios |
| p1_all19 |
3940-3963 |
Outcome |
denotes |
vaginal delivery's UTI. |
| p2_o30 |
3968-3987 |
Physical |
denotes |
rate of SSI and UTI |
| p1_all20 |
3968-4013 |
Outcome |
denotes |
rate of SSI and UTI after cesarean deliveries |
| p1_all21 |
4110-4132 |
Outcome |
denotes |
SSI and UTI odd ratios |
| p2_o31 |
4110-4132 |
Physical |
denotes |
SSI and UTI odd ratios |
| p1_all22 |
4727-4771 |
Intervention |
denotes |
Participation of healthcare facilities (HCF) |
| p1_all23 |
5019-5036 |
Outcome |
denotes |
Incidence of BBFE |
| p2_o36 |
5019-5036 |
Physical |
denotes |
Incidence of BBFE |
| p1_all24 |
5373-5395 |
Outcome |
denotes |
BBFE overall incidence |
| p1_all25 |
5557-5574 |
Outcome |
denotes |
HCV or HIV status |
| p2_o40 |
5557-5574 |
Physical |
denotes |
HCV or HIV status |
| p1_all26 |
5641-5672 |
Outcome |
denotes |
Post-exposure prophylaxis (PEP) |
| p2_o42 |
5928-5932 |
Physical |
denotes |
BBFE |
| p1_all27 |
6373-6396 |
Outcome |
denotes |
Compliance to glove use |
| p2_o45 |
6373-6396 |
Other |
denotes |
Compliance to glove use |
| p2_o45 |
6448-6462 |
Physical |
denotes |
BBFE incidence |
| p2_o46 |
6542-6556 |
Physical |
denotes |
BBFE incidence |
| p2_i2 |
6684-6694 |
Pharmacological |
denotes |
AES-Raisin |
| p2_o47 |
6851-6882 |
Physical |
denotes |
incidence of some types of BBFE |
| p1_all28 |
6851-6883 |
Outcome |
denotes |
incidence of some types of BBFE. |
| p2_i3 |
6968-6981 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all29 |
6968-7030 |
Intervention |
denotes |
chlorhexidine in 70% alcohol compared with 10% povidone-iodine |
| p2_i4 |
7015-7030 |
Pharmacological |
denotes |
povidone-iodine |
| p1_all30 |
7339-7358 |
Outcome |
denotes |
contamination rates |
| p1_all31 |
7532-7545 |
Intervention |
denotes |
chlorhexidine |
| p2_i5 |
7532-7545 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all32 |
7663-7705 |
Outcome |
denotes |
efficacy of venipuncture site disinfection |
| p2_o53 |
7663-7705 |
Other |
denotes |
efficacy of venipuncture site disinfection |
| p1_all33 |
7714-7727 |
Intervention |
denotes |
chlorhexidine |
| p2_i6 |
7714-7727 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all34 |
7761-7776 |
Intervention |
denotes |
povidone-iodine |
| p2_i7 |
7761-7776 |
Pharmacological |
denotes |
povidone-iodine |
| p2_o53 |
7791-7818 |
Physical |
denotes |
blood culture contamination |
| p1_all35 |
7791-7819 |
Outcome |
denotes |
blood culture contamination. |
| p1_all36 |
7913-8097 |
Population |
denotes |
all patients hospitalised in Internal Medicine wards and attended at emergency department at King Chulalongkorn Memorial Hospital, Bangkok, Thailand from August 15 to October 31, 2006. |
| p2_i8 |
8170-8221 |
Pharmacological |
denotes |
chlorhexidine in 70% alcohol or 10% povidone-iodine |
| p1_all37 |
8170-8241 |
Intervention |
denotes |
chlorhexidine in 70% alcohol or 10% povidone-iodine, and blood cultures |
| p1_all38 |
8291-8323 |
Outcome |
denotes |
blood culture contamination rate |
| p2_o56 |
8291-8323 |
Physical |
denotes |
blood culture contamination rate |
| p1_all39 |
8488-8525 |
Outcome |
denotes |
contamination rate for blood cultures |
| p2_o58 |
8488-8525 |
Physical |
denotes |
contamination rate for blood cultures |
| p1_all40 |
8535-8548 |
Intervention |
denotes |
chlorhexidine |
| p2_i9 |
8653-8668 |
Pharmacological |
denotes |
povidone-iodine |
| p1_all41 |
8653-8669 |
Intervention |
denotes |
povidone-iodine. |
| p1_all42 |
8698-8716 |
Outcome |
denotes |
contamination rate |
| p2_o59 |
8698-8716 |
Other |
denotes |
contamination rate |
| p1_all43 |
8768-8781 |
Intervention |
denotes |
chlorhexidine |
| p2_i10 |
8768-8781 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all44 |
8805-8820 |
Intervention |
denotes |
povidone-iodine |
| p2_i11 |
8805-8820 |
Pharmacological |
denotes |
povidone-iodine |
| p1_all45 |
8877-8895 |
Outcome |
denotes |
contamination rate |
| p2_o60 |
8877-8895 |
Other |
denotes |
contamination rate |
| p1_all46 |
8948-8961 |
Intervention |
denotes |
chlorhexidine |
| p2_i12 |
8948-8961 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all47 |
8985-9000 |
Intervention |
denotes |
povidone-iodine |
| p2_i13 |
8985-9000 |
Pharmacological |
denotes |
povidone-iodine |
| p1_all48 |
9069-9101 |
Outcome |
denotes |
coagulase-negative staphylococci |
| p1_all49 |
9124-9137 |
Intervention |
denotes |
chlorhexidine |
| p2_i14 |
9124-9137 |
Pharmacological |
denotes |
chlorhexidine |
| p1_all50 |
9172-9187 |
Intervention |
denotes |
povidone-iodine |
| p2_i15 |
9172-9187 |
Pharmacological |
denotes |
povidone-iodine |
| p1_all51 |
9270-9300 |
Intervention |
denotes |
inanimate hospital environment |
| p2_i16 |
9270-9300 |
Educational |
denotes |
inanimate hospital environment |
| p1_all52 |
9352-9398 |
Intervention |
denotes |
Hydrogen peroxide vapour (HPV) decontamination |
| p2_i17 |
9352-9398 |
Pharmacological |
denotes |
Hydrogen peroxide vapour (HPV) decontamination |
| p1_all53 |
9594-9746 |
Intervention |
denotes |
methicillin-resistant Staphylococcus aureus (MRSA), vancomycinresistant enterococci (VRE) and gentamicin-resistant Gram-negative rod (GNR) contamination |
| p2_i18 |
9688-9746 |
Physical |
denotes |
gentamicin-resistant Gram-negative rod (GNR) contamination |
| p1_all54 |
10157-10184 |
Outcome |
denotes |
Environmental contamination |
| p2_o68 |
10157-10184 |
Physical |
denotes |
Environmental contamination |
| p1_all55 |
10577-10632 |
Outcome |
denotes |
Substantial recontamination towards pre-cleaning levels |
| p2_i19 |
11040-11112 |
Educational |
denotes |
knowledge level and behaviour models of hospital cleaning staff about NI |
| p1_all56 |
11139-11186 |
Population |
denotes |
1788 bedded tertiary care educational hospital. |
| p1_all57 |
11833-11973 |
Population |
denotes |
Results: A total of 240 of 290 (82.7% of total, 122 male, 118 female, aged 36.2±8.7) hospital cleaning staff volunteered to enter the study. |
| p2_p0 |
11881-11884 |
Sample-size |
denotes |
122 |
| p2_p1 |
11885-11889 |
Sex |
denotes |
male |
| p2_p2 |
11891-11894 |
Sample-size |
denotes |
118 |
| p2_p3 |
11895-11901 |
Sex |
denotes |
female |
| p1_all58 |
12136-12156 |
Outcome |
denotes |
Mean knowledge level |
| p2_o83 |
12136-12156 |
Other |
denotes |
Mean knowledge level |
| p1_all59 |
12186-12201 |
Outcome |
denotes |
Knowledge level |
| p2_o84 |
12186-12201 |
Mental |
denotes |
Knowledge level |
| p1_all60 |
12234-12294 |
Outcome |
denotes |
educational status and duration of working as cleaning staff |
| p2_o84 |
12234-12294 |
Other |
denotes |
educational status and duration of working as cleaning staff |
| p1_all61 |
12310-12351 |
Outcome |
denotes |
mean knowledge level of the staff working |
| p1_all62 |
12539-12559 |
Outcome |
denotes |
mean knowledge level |
| p1_all63 |
13086-13136 |
Intervention |
denotes |
Periodical well-established educational programmes |
| p1_all64 |
13201-13251 |
Intervention |
denotes |
Methicillin-resistant Staphylococcus aureus (MRSA) |
| p2_i20 |
13201-13251 |
Pharmacological |
denotes |
Methicillin-resistant Staphylococcus aureus (MRSA) |
| p1_all65 |
13469-13550 |
Intervention |
denotes |
new molecular dipstick assay GenoQuick ® MRSA (Hain Lifescience, Nehren, Germany) |
| p2_o94 |
13633-13668 |
Other |
denotes |
analytical specificity of the assay |
| p1_all66 |
13754-13876 |
Intervention |
denotes |
methicillin-susceptible S. aureus (MSSA) and 38 coagulase-negative staphylocococi (CoNS) of different culture collections. |
| p1_all67 |
14082-14095 |
Outcome |
denotes |
MRSA carriage |
| p1_all68 |
14632-14663 |
Outcome |
denotes |
lower detection limit of 25 CFU |
| p1_all69 |
15156-15178 |
Outcome |
denotes |
diagnostic sensitivity |
| p2_o107 |
15156-15178 |
Other |
denotes |
diagnostic sensitivity |
| p1_all70 |
15194-15216 |
Outcome |
denotes |
diagnostic specificity |
| p2_o107 |
15194-15216 |
Other |
denotes |
diagnostic specificity |
| p2_i21 |
15517-15547 |
Physical |
denotes |
GenoQuick MRSA dip stick assay |
| p1_all71 |
16301-16341 |
Outcome |
denotes |
frequency of positive S. aureus cultures |
| p2_o113 |
16301-16341 |
Physical |
denotes |
frequency of positive S. aureus cultures |
| p1_all72 |
16449-16514 |
Intervention |
denotes |
sterile polyester fiber-tipped swab moistened with sterile saline |
| p2_i22 |
16449-16514 |
Pharmacological |
denotes |
sterile polyester fiber-tipped swab moistened with sterile saline |
| p2_p4 |
16888-16891 |
Sample-size |
denotes |
905 |
| p1_all73 |
16888-16954 |
Population |
denotes |
905 individuals were screened for S. aureus between 2000 and 2005. |
| p1_all74 |
16991-17024 |
Population |
denotes |
54 individuals who were excluded. |
| p1_all75 |
17025-17043 |
Outcome |
denotes |
Overall, S. aureus |
| p1_all76 |
17624-17678 |
Outcome |
denotes |
MRSA rates in a hospital in the North-East of Scotland |
| p1_all77 |
18022-18078 |
Intervention |
denotes |
replacing sodium hypochlorite with a standard detergent. |
| p2_i23 |
18032-18051 |
Pharmacological |
denotes |
sodium hypochlorite |
| p1_all78 |
18298-18324 |
Outcome |
denotes |
infection control measures |
| p1_all79 |
18516-18526 |
Outcome |
denotes |
MRSA rates |
| p2_o131 |
18559-18582 |
Mental |
denotes |
environmental screening |
| p1_all80 |
18595-18645 |
Outcome |
denotes |
use of hypochlorite for environmental disinfection |
| p2_o131 |
18595-18645 |
Mental |
denotes |
use of hypochlorite for environmental disinfection |
| p1_all81 |
18659-18697 |
Outcome |
denotes |
use of alcohol based hand disinfection |
| p2_o131 |
18659-18697 |
Other |
denotes |
use of alcohol based hand disinfection |
| p1_all82 |
18713-18740 |
Outcome |
denotes |
patient admission screening |
| p2_o131 |
18713-18740 |
Other |
denotes |
patient admission screening |
| p1_all83 |
19122-19142 |
Outcome |
denotes |
clinical MRSA cases. |
| p1_all84 |
19335-19460 |
Population |
denotes |
Portuguese piggery samples and to analyse antibiotic resistance genes among these strains after European growth promoter ban. |
| p1_all85 |
19607-19666 |
Intervention |
denotes |
selective Slanetz-Bartley agar with or without antibiotics. |
| p1_all86 |
19880-20030 |
Outcome |
denotes |
Detection of genes coding for resistance [vanA, B, C1, C2, ermA, B, C, tetM, L, O, K, S, aac(6 )-Ie-aph(2 )-Ia, aph(2 )-Ib,Ic,Id, aph(3 )-IIIa, vat E] |
| p2_i24 |
20235-20247 |
Pharmacological |
denotes |
tetracycline |
| p1_all87 |
20235-20305 |
Intervention |
denotes |
tetracycline, minocycline, erythromycin, and quinupristin-dalfopristin |
| p2_i25 |
20249-20260 |
Pharmacological |
denotes |
minocycline |
| p2_i26 |
20262-20274 |
Pharmacological |
denotes |
erythromycin |
| p2_i27 |
20280-20305 |
Pharmacological |
denotes |
quinupristin-dalfopristin |
| p1_all88 |
20368-20450 |
Outcome |
denotes |
high-level of resistance (HLR) of streptomycin, nitrofurantoin, ciprofloxacin, HLR |
| p2_i28 |
20432-20445 |
Pharmacological |
denotes |
ciprofloxacin |
| p2_i29 |
20454-20464 |
Pharmacological |
denotes |
gentamicin |
| p1_all89 |
20454-20496 |
Intervention |
denotes |
gentamicin, chloramphenicol and ampicillin |
| p2_i30 |
20466-20481 |
Pharmacological |
denotes |
chloramphenicol |
| p2_i31 |
20486-20496 |
Pharmacological |
denotes |
ampicillin |
| p2_o146 |
20787-20792 |
Physical |
denotes |
vanC1 |
| p1_all90 |
21733-21741 |
Intervention |
denotes |
NORM-VET |
| p1_all91 |
22190-22211 |
Outcome |
denotes |
(indicator bacteria) |
| p2_o156 |
22190-22211 |
Physical |
denotes |
(indicator bacteria) |
| p2_i32 |
22414-22448 |
Physical |
denotes |
microdilution technique (VetMICTM) |
| p1_all92 |
22414-22449 |
Intervention |
denotes |
microdilution technique (VetMICTM). |
| p1_all93 |
22454-22487 |
Outcome |
denotes |
minimum inhibitory concentrations |
| p2_o159 |
22454-22487 |
Physical |
denotes |
minimum inhibitory concentrations |
| p1_all94 |
24510-24624 |
Population |
denotes |
owners and their dogs was performed using a convenience sample of 800 pairs recruited at six veterinary practices. |
| p1_all95 |
24801-24914 |
Intervention |
denotes |
questionnaire providing demographic information of owner and dog, and stating if the dog had received antibiotics |
| p1_all96 |
24968-25050 |
Intervention |
denotes |
blood agar and mannitol salt agar and placed in 5% salt meat broth for enrichment. |
| p2_i33 |
24983-25034 |
Pharmacological |
denotes |
mannitol salt agar and placed in 5% salt meat broth |
| p1_all97 |
25256-25283 |
Outcome |
denotes |
Antibiotic susceptibilities |
| p2_i34 |
25557-25579 |
Pharmacological |
denotes |
oxacillin, clindamycin |
| p1_all98 |
25557-25622 |
Intervention |
denotes |
oxacillin, clindamycin, gentamicin, tetracycline and fusidic acid |
| p2_i35 |
25581-25591 |
Pharmacological |
denotes |
gentamicin |
| p2_i36 |
25593-25605 |
Pharmacological |
denotes |
tetracycline |
| p2_i37 |
25610-25622 |
Pharmacological |
denotes |
fusidic acid |
| p1_all99 |
25782-25804 |
Outcome |
denotes |
Methicillin resistance |
| p2_i38 |
25837-25852 |
Pharmacological |
denotes |
chloramphenicol |
| p1_all100 |
25837-25898 |
Intervention |
denotes |
chloramphenicol, clindamycin, tetracycline, and cotrimoxazole |
| p2_i39 |
25854-25865 |
Pharmacological |
denotes |
clindamycin |
| p2_i40 |
25867-25879 |
Pharmacological |
denotes |
tetracycline |
| p2_i41 |
25885-25898 |
Pharmacological |
denotes |
cotrimoxazole |
| p2_i42 |
25941-25957 |
Pharmacological |
denotes |
fluoroquinolones |
| p1_all101 |
25941-25972 |
Intervention |
denotes |
fluoroquinolones and gentamicin |
| p2_i43 |
25962-25972 |
Pharmacological |
denotes |
gentamicin |
| p1_all102 |
26022-26044 |
Outcome |
denotes |
Methicillin resistance |
| p2_o188 |
26078-26109 |
Physical |
denotes |
resistance to other antibiotics |
| p1_all103 |
26453-26513 |
Population |
denotes |
(Ent) from healthy food animals at slaughter across the EU. |
| p1_all104 |
26916-26994 |
Population |
denotes |
total 1465 Ec were recovered (cattle n = 490, pigs n = 494, chickens n = 481). |
| p1_all105 |
26995-27010 |
Outcome |
denotes |
Mean resistance |
| p1_all106 |
27027-27037 |
Intervention |
denotes |
ampicillin |
| p2_i44 |
27071-27081 |
Pharmacological |
denotes |
cefotaxime |
| p1_all107 |
27093-27106 |
Intervention |
denotes |
ciprofloxacin |
| p2_i45 |
27093-27106 |
Pharmacological |
denotes |
ciprofloxacin |
| p1_all108 |
27165-27175 |
Intervention |
denotes |
gentamicin |
| p1_all109 |
27189-27201 |
Intervention |
denotes |
tetracycline |
| p2_i46 |
27189-27201 |
Pharmacological |
denotes |
tetracycline |
| p1_all110 |
27217-27246 |
Intervention |
denotes |
trimethoprim-sulfamethoxazole |
| p2_i47 |
27217-27246 |
Pharmacological |
denotes |
trimethoprim-sulfamethoxazole |
| p1_all111 |
27366-27525 |
Population |
denotes |
A total of 718 Ent isolates were recovered, comprising 356 E. faecium, 83 E. faecalis and 279 other species including E. durans, E. hirae and E. casseliflavus. |
| p2_i48 |
27578-27587 |
Pharmacological |
denotes |
linezolid |
| p1_all112 |
27578-27588 |
Intervention |
denotes |
linezolid. |
| p1_all113 |
27897-27915 |
Outcome |
denotes |
G and V resistance |
| p2_o204 |
27897-27915 |
Physical |
denotes |
G and V resistance |
| p1_all114 |
27952-27969 |
Outcome |
denotes |
resistance to Q/D |
| p1_all115 |
28149-28163 |
Outcome |
denotes |
Q/D resistance |
| p2_o210 |
28463-28487 |
Physical |
denotes |
antimicrobial resistance |
| p2_o211 |
28646-28676 |
Physical |
denotes |
antimicrobial resistance rates |
| p2_i49 |
28788-28797 |
Pharmacological |
denotes |
linezolid |
| p1_all116 |
28788-28813 |
Intervention |
denotes |
linezolid and vancomycin. |
| p2_i50 |
28802-28812 |
Pharmacological |
denotes |
vancomycin |
| p1_all117 |
29436-29498 |
Intervention |
denotes |
Streptococcus pneumoniae (SPN) and Haemophilus influenzae (HI) |
| p1_all118 |
29574-29599 |
Outcome |
denotes |
MICs and susceptibilities |
| p1_all119 |
29925-29937 |
Outcome |
denotes |
sputum & BAL |
| p2_o221 |
29925-29937 |
Physical |
denotes |
sputum & BAL |
| p1_all120 |
29949-29954 |
Outcome |
denotes |
blood |
| p2_o221 |
29949-29954 |
Physical |
denotes |
blood |
| p1_all121 |
29965-29976 |
Outcome |
denotes |
nasopharynx |
| p2_o221 |
29965-29976 |
Physical |
denotes |
nasopharynx |
| p1_all122 |
30002-30007 |
Outcome |
denotes |
sinus |
| p1_all123 |
30116-30182 |
Outcome |
denotes |
SPN penicillin and erythromycin resistance (PR and ER) prevalences |
| p2_o223 |
30116-30182 |
Physical |
denotes |
SPN penicillin and erythromycin resistance (PR and ER) prevalences |
| p1_all124 |
30425-30427 |
Outcome |
denotes |
PR |
| p2_o225 |
30425-30427 |
Physical |
denotes |
PR |
| p1_all125 |
30459-30470 |
Outcome |
denotes |
Falls in PR |
| p2_o226 |
30459-30470 |
Physical |
denotes |
Falls in PR |
| p2_i51 |
30508-30520 |
Pharmacological |
denotes |
Erythromycin |
| p1_all126 |
30508-30531 |
Outcome |
denotes |
Erythromycin resistance |
| p2_o227 |
30508-30531 |
Physical |
denotes |
Erythromycin resistance |
| p1_all127 |
30790-30825 |
Outcome |
denotes |
Betalactamase (BL) production in HI |
| p2_o230 |
30790-30825 |
Physical |
denotes |
Betalactamase (BL) production in HI |
| p2_o230 |
30865-30909 |
Physical |
denotes |
BL negative and ampicillin resistant (BLNAR) |
| p1_all128 |
30911-30936 |
Outcome |
denotes |
BL production frequencies |
| p2_o231 |
30911-30936 |
Physical |
denotes |
BL production frequencies |
| p1_all129 |
30998-31011 |
Intervention |
denotes |
Telithromycin |
| p1_all130 |
31021-31039 |
Outcome |
denotes |
sustained activity |
| p1_all131 |
31337-31350 |
Intervention |
denotes |
Telithromycin |
| p1_all132 |
31946-31972 |
Population |
denotes |
13 European (EUR) nations. |
| p1_all133 |
31973-32046 |
Outcome |
denotes |
Trends in S and the occurrences of well defined resistance (R) mechanisms |
| p2_o237 |
31973-32046 |
Physical |
denotes |
Trends in S and the occurrences of well defined resistance (R) mechanisms |
| p1_all134 |
32087-32153 |
Intervention |
denotes |
community-acquired respiratory tract infections (CA-RTI) pathogens |
